2016

October 06 2016
BTG plc: close period update

06 October 2016 BTG plc (LSE: BTG), the specialist healthcare company, announces the following update for the six months to 30 September 2016 ahead of the publication of its Interim Results on 15...

October 06, 2016
BTG: settlement of US government investigation into LC Bead®

London, UK, 06 October 2016 BTG plc (LSE: BTG), the specialist healthcare company, announces that its Biocompatibles, Inc. subsidiary has reached a settlement with the US government in relation to...

September 09 2016
BTG launches BETA™ Radiation Safety Programme, to reduce the risk of radiation exposure for healthcare professionals and patients

London, UK, 09 September 2016 LONDON, UK: BTG plc (LSE: BTG), an international specialist healthcare company, today announced the launch of the βETA™ Radiation Safety Programme, a new...

August 23, 2016
BTG receives Health Canada approval for DC Bead LUMI™ First commercially available radiopaque drug-eluting bead in Canada that provides real-time visible confirmation of bead location during embolization for the treatment of tumours in patients with HCC and mCRC

Ottawa, Canada, 23 August 2016 BTG International Canada Inc., part of the global specialist healthcare company BTG (LSE:BTG), today announced that it has received approval from Health Canada for...

August 17, 2016
CMS Grants Vistogard® New Technology Add-on Payment Status Effective 1 October 2016

West Conshohocken, PA, 17 August 2016 BTG plc (LSE: BTG), the specialist healthcare company, today announces that Centers for Medicare and Medicaid Services (CMS) has approved a New Technology...

Show 5102550100 per page
Top